M
MabVax Therapeutics
Biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies
About MabVax Therapeutics
MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company specializing in the discovery and rapid clinical development of fully human antibodies aimed at addressing unmet medical needs in cancer treatment. The company's core product, MVT-5873, is a fully human IgG1 monoclonal antibody targeting sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials for pancreatic cancer and other CA19-9 positive tumors. MabVax collaborates with renowned institutions such as Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health, and Imaging Endpoints. To date, 50 patients have been treated with either MVT-5873 or the PET imaging diagnostic product MVT-2163 in Phase 1 clinical studies, demonstrating early safety, target specificity, and potential efficacy. The company has also commenced patient dosing for its radioimmunotherapy product MVT-1075 in a Phase 1 clinical study. MabVax operates in the biotechnology sector, primarily serving the oncology market, and generates revenue through the development and potential commercialization of its antibody-based therapies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2014
News
Open roles
MabVax Therapeutics in the San Diego ecosystem
The MabVax Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Biomark Capital- NINumoda Capital Innovations
Burrill
Series B and later2 investors entered at this stage
Boehringer Ingelheim
TRITON FUNDS
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MabVax Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MabVax Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


